Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

E. Brown, Christine; Alizadeh, Darya; Starr, Renate; Weng, Lihong; R. Wagner, Jamie; Naranjo, Araceli; R. Ostberg, Julie; Suzette Blanchard, M.; Kilpatrick, Julie; Simpson, Jennifer; Kurien, Anita; J. Priceman, Saul; Wang, Xiuli; L. Harshbarger, Todd; D’Apuzzo, Massimo; A. Ressler, Julie; C. Jensen, Michael; E. Barish, Michael; Y. Chen, Mike; Portnow, Jana; J. Forman, Stephen; Badie, Behnam

doi:10.1056/nejmoa1610497

Public

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Published in New England Journal of Medicine • Dec 28, 2016

Authors:

Christine E. Brown

Darya Alizadeh

Renate Starr

Abstract

A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes - ...

Subject

Chimeric antigen receptor

Medicine

Antigen

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!